Nantes, France

Cédric Bes

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 40(Granted Patents)


Location History:

  • Ambilly, FR (2011)
  • Villevieille, FR (2013)
  • Nantes, FR (2014 - 2018)

Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Cédric Bes: Innovator in Antibody Development

Introduction

Cédric Bes is a prominent inventor based in Nantes, France, known for his significant contributions to the field of biotechnology. With a total of eight patents to his name, he has made remarkable strides in the development of antibody technologies aimed at treating cancer.

Latest Patents

Among his latest patents is a method for generating and screening an antibody library. This invention pertains to a method for creating a DNA sequence that codes for the heavy or light chain of at least one antibody derived from RNA of a cell capable of producing an antibody. Specifically, it focuses on generating a monoclonal antibody library and utilizing this library for screening monoclonal antibodies, particularly human antibodies, for cancer treatment. Another notable patent is the Anti-cMET antibody, which is designed to bind specifically to the human c-Met receptor. This antibody is capable of inhibiting the tyrosine kinase activity of the receptor with improved antagonistic activity. The invention includes a composition comprising this antibody antagonist to c-Met and its application as a medicament for cancer treatment.

Career Highlights

Cédric Bes is currently associated with Pierre Fabre Medicament, where he continues to innovate in the field of antibody research. His work has been instrumental in advancing therapeutic options for cancer patients.

Collaborations

He collaborates with notable colleagues such as Liliane Goetsch and Thierry Wurch, contributing to a dynamic research environment that fosters innovation.

Conclusion

Cédric Bes stands out as a key figure in the biotechnology sector, particularly in the development of novel antibody therapies for cancer treatment. His patents reflect a commitment to improving medical outcomes through innovative research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…